Page 4 - Nasdaq Cbay News Today

Golden State Equity Partners purchased a new position in CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 50,000 shares of the biopharmaceutical company’s stock, valued at approximately $436,000. A number of other hedge funds have […]

NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on...

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price objective increased by Raymond James from $17.00 to $33.00 in a research report report published on Thursday morning, Marketbeat.com reports. The brokerage currently has a strong-buy rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. BTIG Research increased their […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report)’s share price traded up 7.9% during trading on Monday after BTIG Research raised their price target on the stock from $22.00 to $24.00. BTIG Research currently has a buy rating on the stock. CymaBay Therapeutics traded as high as $17.55 and last traded at $17.53. 938,534 shares […]

Affinity Asset Advisors LLC trimmed its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 5.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,083,118 shares of the biopharmaceutical company’s stock after selling 60,413 shares during the quarter. CymaBay Therapeutics […]

Logos Global Management LP trimmed its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 68.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 400,000 shares of the biopharmaceutical company’s stock after selling 850,000 shares during the period. Logos […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report)’s share price gapped up before the market opened on Friday after BTIG Research raised their price target on the stock from $22.00 to $24.00. The stock had previously closed at $15.01, but opened at $15.42. CymaBay Therapeutics shares last traded at $16.50, with a volume of 795,248 […]

CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $21.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 40.28% from […]

CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report released on Thursday, Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 9.41% from the company’s previous close. Other […]

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price target increased by Jonestrading from $13.00 to $15.00 in a research report report published on Tuesday, Benzinga reports. Jonestrading currently has a buy rating on the biopharmaceutical company’s stock. CBAY has been the subject of several other research reports. Guggenheim began coverage on shares of CymaBay […]